Quantitative electroencephalography (qEEG) is a powerful supplement to the conventional EEG, providing reproducible estimates that may be compared over time, and enables the discovery of phenomena that may not be detected by conventional visual inspection of the EEG (1).
Dementia occurs frequently in patients with advanced Parkinson's disease (PD) (2) . In these patients a slowing of the background activity is observed when compared with normal controls or non-demented PD patients (in whom the EEG is usually normal). The EEG abnormalities often parallel the degree of change in the patient's mental condition (3) (4) (5) (6) .
Rivastigmine is an inhibitor of both acetylcholinesterase and butyrylcholinesterase and has central nervous system selectivity (7) . In a double-blind study of patients with mild to moderately severe Alzheimer's disease, statistically significant improvements of cognitive functions and global assessments were observed after 6 months of treatment with rivastigmine (8) . It was symptomatically effective and safe in these patients at a daily dose of 6-12 mg. In addition, rivastigmine was found to have significant behavioral symptomatic effects in dementia with Lewy bodies. Parameters of cognitive performance, in particular speed-related functions, were also significantly improved in these patients (9) .
Dementia in PD has been associated with the cholinergic cell loss in the nucleus basalis of Meynert, being more prominent in demented PD patients than in PD patients without dementia (10, 11) . A small open trial has indeed shown that tacrine, an acetylcholinesterase inhibitor, improved cognitive functions in PD patients with dementia (12) . We therefore speculated that rivastigmine will also be effective in PD patients with dementia. We also expected that the treatment will increase higher frequency activity in the qEEG and decrease slow-wave activity, with concomitant improvement in the cognitive state of the patients. The effect of rivastigmine on the cognitive state of the current patients is discussed elsewhere (13) . Objectives -Quantitative electroencephalogram (qEEG) can be used to measure the effects of drugs on the brain. We studied the effects of rivastigmine on the qEEG in Parkinson's disease (PD) patients with dementia. Subjects and methods -Demented PD patients (n ¼ 19) were treated with rivastigmine in an open label study. Recordings were obtained prior to and following 12 weeks of treatment. Results were analyzed using two-way ANOVA with repeated measures. Results -A significant increase in the relative alpha (P < 0.05) activity was observed after treatment with rivastigmine. This was general rather than localized to specific brain surface areas. An increase in beta activity and decrease in the slower frequencies (delta and theta) were also observed; however, these were not statistically significant. Conclusion -qEEG may serve as an objective tool to monitor the effects of antidementia drug therapy. The changes characterized by increased faster frequencies and decreased slower frequencies that were observed may indicate increased arousal or improvement in the cognitive state of the patients as a consequence of the treatment with rivastigmine. 
Subjects
This was an open-label study consisting of 19 patients with slight to moderate cognitive impairment, who were diagnosed as suffering from PD at least 1 year prior to the appearance of the dementia. The diagnosis of PD was based on accepted clinical criteria (14) . Screening of patients was performed using the following criteria: medical history, neurological exam, MiniMental State Examination, Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) (15) , and anatomic visualization using computed tomography ⁄ magnetic resonance imaging, to exclude silent strokes or other structural brain lesions.
Patients were treated with rivastigmine at an initial dose of 3 mg ⁄ day, and gradually increased up to 12 mg ⁄ day, dependent on individual patient tolerance. Quantitative EEG recordings were performed at baseline and following 12 weeks of treatment.
Clinical and cognitive assessment
Clinical impression of change, Unified Parkinson's Disease Rating Scale and ADAS-Cog were assessed at baseline and after 12 weeks of treatment with rivastigmine. The methodology is detailed elsewhere (13) .
Electroencephalogram
The EEG was recorded on an 18-channel Grass machine model 8 (Grass, Quincey, MA, USA) that was connected to a Bio-logic Brain Atlas commercial computer system (NEC, Tokyo, Japan) with data acquisition and field mapping capabilities for 21 electrodes. Disc electrodes were applied to the scalp with collodion, according to the international 10-20 system. Linked mandibular electrodes were used as reference.
We used low linear frequency filter of 1 Hz, high linear frequency filter of 35 Hz as well as a 50-Hz notch filter. Signals were digitized at 128 samples ⁄ s.
Calibration was performed using an input signal of 100 lV, which was delivered to each channel. The output signal was then checked to be the same in all channels.
All EEGs were recorded at noon, in a resting awake condition with eyes closed. The alertness of the patients was maintained by frequent auditory stimuli and verbal communication. Up to 5 min of EEG were stored in the computer system, allowing an on-line visual inspection of the EEG trace on the computer screen. Sixteen 2-s artifact free samples (total of 32 s) were selected by visual inspection. The selection was done randomly, although the person who made the selection (NF) was aware of whether the EEG has been done while the patient was medicated or not. Before the spectral analysis we recomputed all EEG leads based on the digital computer averaged reference. A fast Fourier transformation was performed on the samples, which were then averaged. To continue the analysis on a PC computer, the files were then copied as ASCII files.
Quantitative EEG was compared at the four 4-Hz wide frequency bands -delta (0-3.5 Hz), theta (4-7.5 Hz), alpha (8-11.5 Hz) and beta1 (12-15.5 Hz), in addition to beta2 (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) .
Using the computer software, the average amplitude was calculated for each electrode in each of the five frequency bands. This was followed by a calculation of absolute mean amplitude (a) and relative mean amplitude (r). Relative amplitude was defined as the mean amplitude of a given frequency divided by the total mean amplitude of the same patient at the same time.
Different scalp derivations were chosen to represent different regions of the brain. The following regions were defined for four independent statistical comparisons:
Comparison no. 1: Frontal -F7, F3, Fz, F4, F8, central -C3, Cz, C4, parieto-occipital -P3, Pz, P4, O1, Oz, O2, temporal -T3, T5, T4, T6.
Comparison no. 2: Anterior -F7, F3, Fz, F4, F8, C3, Cz, C4, posterior -T3, T5, P3, Pz, P4, T6, T4, O1, Oz, O2.
Comparison no. 3: Left hemisphere -F7, T3, T5, F3, C3, P3, O1, right hemisphere -F8, T4, T6, F4, C4, P4, O2.
Comparison no. 4: The whole brain frequency spectra were calculated from 18 electrodes.
For the statistical analysis, in order to approach normal distributions, natural logarithmic (ln) transformation was performed on the absolute mean amplitude values (a), and ln [r ⁄ (1 ) r)] was used on the relative mean amplitudes (r). The values obtained after the logarithmic transformation from the relevant electrodes in each region were then averaged.
Peak frequencies in the alpha activity range before and after treatment were determined using the frequency between 8 and 12 Hz from either O1 or O2 -whichever had the higher amplitude in a given subject.
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Statistical analysis
Statistical analysis was performed by means of a two-way analysis of variance (ANOVA, at a significance level of P < 0.05) with repeated measures. Comparisons were made at each of the frequency bands. Differences were calculated before and after treatment (treatment effects), and among different brain regions (comparison between areas). Significant interactions between the changes over time and the changes in different areas were calculated, reflecting the different effects of the treatment in different regions at each frequency band (area-treatment interactions). Each subject functioned as his ⁄ her own control as the repeated measures were performed on the same individuals.
Statistical comparisons of peak frequencies were performed by means of two-tailed paired Student's t-test.
The strength of correlation between changes in qEEG variables and in cognitive assessment scores was calculated using Spearman's rank order correlation coefficient.
Results
Demographics for the study population are shown in Table 1 .
Quantitative EEG
Absolute amplitude -Rivastigmine treatment was associated with increases in the mean absolute amplitudes of alpha and beta and decreases in the mean absolute amplitudes of delta and theta ( Table 2 ). The increase in the mean absolute alpha activity was bilateral, with a greater change seen over the left hemisphere compared with the right (P ¼ 0.048). However, the area-treatment interactions for this analysis were not statistically significant. No significant treatment effects were observed for the other frequency bands, and there were no significant area-treatment interactions for any of the analyses in the absolute amplitude bands.
Relative amplitude -The treatment with rivastigmine produced a significant increase in the mean relative amplitude of alpha (P ¼ 0.019; Table 2 ).
The mean relative amplitude of beta1 also increased, although non-significantly (P ¼ 0.059). In addition a decrease in relative delta and theta was observed; however, these were not statistically significant. Although there were significant amplitude differences between areas, no significant areatreatment interactions were observed.
Peak frequency -There was a slight non-significant increase in the peak alpha frequency as a result of the treatment (from 8.3 AE 0.7 to 8.4 AE 0.5 Hz). The mean amplitude at this frequency, increased with borderline significance from 3.7 AE 2.2 to 4.3 AE 2.7 lV (P ¼ 0.051).
Correlations
Improvements in cognitive scores were seen, but no statistical correlation was found between these changes and the qEEG changes in the relative alpha amplitude. Likewise, no significant correlations between the changes in absolute alpha activity in either the left or the right hemispheres and changes in cognitive scores were observed.
Discussion
We observed a significant increase in the relative alpha activity observed after treatment with rivastigmine. However, there were no significant areatreatment interactions, suggesting that the effect of the treatment was extensive rather than focal, with improvement in broader regions of the brain. Decreases in the absolute and relative slower frequencies of delta and theta, and increases in the absolute and relative beta activity were observed as well; however, these were not statistically significant. The increase in alpha activity under rivastigmine is in line with the EEG changes reported under treatment with the older cholinesterase inhibitor tetrahydroaminoacridine (16, 17) . Furthermore, we have previously demonstrated that the relative alpha amplitude was significantly 
, log (amplitude of EEG at this frequency range during treatment), b, log (amplitude of EEG before treatment). Log(r ⁄ 1 ) r) transforms were used in statistical analysis of the relative amplitudes, *significant difference (ANOVA).
reduced in PD patients with dementia (3). Thus it is relevant that in the present study rivastigmine changed the same parameter towards normality in the demented PD patients. Although in our study we observed cognitive improvement by treatment with rivastigmine (13), these were not correlated with the EEG changes. The qEEG changes observed may be an indication of increased arousal rather than of the improvement in the cognitive state of the patients. The lack of significant correlations between physiological and cognitive changes may favor this conclusion, but could also be because of the small number of patients. More importantly, the neuropsychological measures are subjected to several distractors such as training and placebo effects, and in the present study the clinical raters were not blinded, whereas the EEG measures are objective. However, relaxation as a result habituation to the examination situation could partly affect the results. A more relaxed state could increase the alpha activity, but this would be at the expense of beta, which was not the case in the present study.
In conclusion, the changes characterized by increased faster frequencies and decreased slower frequencies that were observed may be an indication of increased arousal or of an improvement in the cognitive state of the patients as a consequence of the treatment with rivastigmine. These findings may be attributed to an enhancement of cholinergic neurotransmission as a result of inhibition of brain cholinesterase by rivastigmine.
